Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On February 13, 2025, Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, exercised employee stock options to acquire 6,500 shares of common stock at a price of $45.2767 per share.
• Simultaneously, Bobo sold 6,500 shares of common stock in two transactions: 100 shares at $76.26 and 6,400 shares at a weighted average price of $75.7402.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these transactions, Bobo directly owns 53,335.7184 shares of common stock and indirectly owns 38,726.247 shares through a 401(k) and 135,152 shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions executed under a pre-existing plan. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are routine disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider activity and are closely watched by investors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates